Form 8-K
8-K — TERAWULF INC.
Accession: 0001104659-26-044387
Filed: 2026-04-16
Period: 2026-04-14
CIK: 0001083301
SIC: 6199 (FINANCE SERVICES)
Item: Entry into a Material Definitive Agreement
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — tm2611661d9_8k.htm (Primary)
EX-1.1 — EXHIBIT 1.1 (tm2611661d9_ex1-1.htm)
EX-5.1 — EXHIBIT 5.1 (tm2611661d9_ex5-1.htm)
EX-99.1 — EXHIBIT 99.1 (tm2611661d9_ex99-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: tm2611661d9_8k.htm · Sequence: 1
false
0001083301
0001083301
2026-04-14
2026-04-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April
14, 2026
TERAWULF INC.
(Exact name of registrant as specified in its charter)
Delaware
001-41163
87-1909475
(State or other
jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
9 Federal Street
Easton, Maryland
(Address of principal executive offices)
21601
(Zip Code)
Registrant’s telephone number, including
area code: (410) 770-9500
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common stock, par value $0.001 per share
WULF
The Nasdaq Capital Market
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On
April 14, 2026, TeraWulf Inc. (“TeraWulf” or the
“Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley &
Co. LLC, as representative of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed
to sell 47,400,000 shares of the Company’s common stock, par value $0.001 per share (“Common
Stock”), at a public offering price of $19.00 per share (the “Offering”). In connection
with the Offering, the Company granted the Underwriters a 30-day option to purchase up to an additional 7,110,000
shares of Common Stock (the “Optional Shares”). The Offering, including the sale of the Optional Shares, closed on
April 16, 2026.
The
net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, were approximately $1,004.3
million.
The Underwriting Agreement includes customary representations,
warranties and covenants by the Company. It also provides that the Company will indemnify the Underwriters against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
The
sale of Common Stock was made pursuant to the Company’s registration statement on Form S-3ASR (File No. 333-295042) (the “Registration
Statement”), as supplemented by a preliminary prospectus supplement, filed with the Securities and Exchange Commission (the “SEC”)
on April 14, 2026, and a final prospectus supplement, dated April
14, 2026, filed with the SEC on April 16, 2026 pursuant to Rule 424(b) under the Securities
Act.
The foregoing description of the Underwriting Agreement
is not complete and is qualified in its entirety by reference to the complete text of the Underwriting Agreement, a copy of which is attached
as Exhibit 1.1 hereto and incorporated herein by reference.
Item 8.01 Other Events.
On
April 16, 2026, the Company issued a press release announcing the closing of the Offering.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
In connection with the Offering, the legal opinion
as to the legality of the Common Stock sold in the Offering is being filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated
herein and into the Registration Statement by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
1.1
Underwriting Agreement, dated April 14, 2026, by
and among TeraWulf Inc. and Morgan Stanley & Co. LLC, as representative of the several underwriters named therein.
5.1
Opinion of Paul, Weiss, Rifkind, Wharton &
Garrison LLP.
23.1
Consent of Paul, Weiss, Rifkind, Wharton &
Garrison LLP (included in Exhibit 5.1).
99.1
Press release issued by TeraWulf Inc., dated April
16, 2026.
104
Cover Page Interactive Data File (embedded within
the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
April 16, 2026
TERAWULF INC.
By:
/s/ Patrick A. Fleury
Name:
Patrick A. Fleury
Title:
Chief Financial Officer
3
EX-1.1 — EXHIBIT 1.1
EX-1.1
Filename: tm2611661d9_ex1-1.htm · Sequence: 2
Exhibit 1.1
47,400,000 Shares
TERAWULF INC.
Common Stock (par value $0.001 per share)
UNDERWRITING AGREEMENT
April 14,
2026
April 14,
2026
Morgan Stanley & Co. LLC
c/o Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
Ladies and Gentlemen:
TeraWulf Inc., a Delaware corporation (the “Company”),
proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 47,400,000 shares
of its common stock, par value $0.001 per share (the “Firm Shares”). The Company also proposes to issue and sell to
the several Underwriters not more than an additional 7,110,000 shares of its common stock, par value $0.001 per share (the “Additional
Shares”) if and to the extent that Morgan Stanley & Co. LLC (“Morgan Stanley”), shall have determined
to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2
hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares
of common stock, par value $0.001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are
hereinafter referred to as the “Common Stock.”
The Company has filed with the Securities and Exchange
Commission (the “Commission”) a registration statement on Form S-3ASR (File No. 333-295042), covering the
public offering and sale of certain securities, including the Shares, under the Securities Act of 1933, as amended (the “Securities
Act”), which was deemed automatically effective upon filing with the Commission on April 14, 2026 and is hereinafter referred
to as the “Registration Statement”; the prospectus in the form first used to confirm sales of Shares (or in the form
first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities
Act) is hereinafter referred to as the “Prospectus.” If the Company has filed an abbreviated registration statement
to register additional shares of Common Stock pursuant to Rule 462(b) under the Securities Act (a “Rule 462 Registration
Statement”), then any reference herein to the term “Registration Statement” shall be deemed to include such
Rule 462 Registration Statement.
For purposes of this Agreement, “free
writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, “preliminary prospectus”
shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted information
pursuant to Rule 430A under the Securities Act that was used after such effectiveness and prior to the execution and delivery of
this Agreement, “Time of Sale Prospectus” means the preliminary prospectus contained in the Registration Statement
at the time of its effectiveness together with the documents and pricing information set forth in Schedule II hereto, and “broadly
available road show” means a “bona fide electronic road show” as defined in Rule 433(h)(5) under the Securities
Act that has been made available without restriction to any person. As used herein, the terms “Registration Statement,” “preliminary
prospectus,” “Time of Sale Prospectus” and “Prospectus” shall include the documents, if any, incorporated
by reference therein as of the date hereof. The terms “supplement,” “amendment” and “amend”
as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus or the Prospectus shall include
all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), that are deemed to be incorporated by reference therein.
1. Representations
and Warranties. The Company represents and warrants to and agrees with each of the Underwriters that:
(a) The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and
no proceedings for such purpose or pursuant to Section 8A under the Securities Act are pending before or threatened by the Commission.
(b) (i) Each
document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the
Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations
of the Commission thereunder, (ii) The Registration Statement, when it became effective, did not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply and, as amended
or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations
of the Commission thereunder, (iv) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection
with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section 4),
the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading, (v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus,
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading and (vi) the Prospectus does not contain and, as amended
or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations
and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus
or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through Morgan
Stanley expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters through
Morgan Stanley consists of the information described as such in paragraph 8(b) hereof.
2
(c) The
Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities
Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been,
or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except
for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to Morgan
Stanley before first use, the Company has not prepared, used or referred to, and will not, without Morgan Stanley’s prior consent,
prepare, use or refer to, any free writing prospectus.
(d) The
consolidated financial statements of the Company included or incorporated by reference in the Time of Sale Prospectus and the Prospectus,
together with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company
and any subsidiary of the Company that is a significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X promulgated
by the Commission) (each, a “Subsidiary,” and, collectively, the “Subsidiaries”) as of the dates
indicated and the consolidated results of operations, cash flows and changes in stockholders’ equity of the Company and its Subsidiaries
for the periods specified (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material,
either individually or in the aggregate) and have been prepared in compliance with the published requirements of the Securities Act and
the Exchange Act, as applicable, and in conformity with generally accepted accounting principles in the United States (“GAAP”)
applied on a consistent basis (except (i) for such adjustments to accounting standards and practices as are noted therein and (ii) in
the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) during the
periods involved; the other financial and statistical data with respect to the Company and its Subsidiaries contained or incorporated
by reference in the Time of Sale Prospectus and the Prospectus, are accurately and fairly presented and prepared on a basis consistent
with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are
required to be included or incorporated by reference in the Time of Sale Prospectus and the Prospectus that are not included or incorporated
by reference as required; the Company and its Subsidiaries do not have any material liabilities or obligations, direct or contingent (including
any off balance sheet obligations), not described in the Time of Sale Prospectus and the Prospectus which are required to be described
in the Time of Sale Prospectus and the Prospectus; and all disclosures contained or incorporated by reference in the Time of Sale Prospectus
and the Prospectus, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations
of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
Act, to the extent applicable.
3
(e) The
Company and its Subsidiaries, are, and will be, duly organized, validly existing as a corporation and in good standing under the laws
of their respective jurisdictions of organization. The Company and its Subsidiaries are duly licensed or qualified as a foreign corporation
for transaction of business and in good standing under the laws of each other jurisdiction in which their respective ownership or lease
of property or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority
necessary to own or hold their respective properties and to conduct their respective businesses as described in the Company’s filings
with the Commission, except where the failure to be so qualified or in good standing or have such power or authority would not, individually
or in the aggregate, have a material adverse effect on the assets, business, operations, earnings, properties, condition (financial or
otherwise), prospects, stockholders’ equity or results of operations of the Company and its Subsidiaries taken as a whole, or prevent
the consummation of the transactions contemplated hereby (a “Material Adverse Effect”).
(f) The
Company owns directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest,
encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are
fully paid, nonassessable and free of preemptive and similar rights. The Company does not own or control, directly or indirectly, any
corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report
on Form 10-K for the most recently ended fiscal year and other than (i) those subsidiaries not required to be listed on Exhibit 21.1
by Item 601 of Regulation S-K under the Exchange Act and (ii) those subsidiaries formed since the last day of the most recently ended
fiscal year.
(g) This
Agreement has been duly authorized, executed and delivered by the Company.
4
(h) The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus.
(i) The
shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.
(j) The
Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be validly
issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.
(k) The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
any provision of applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding
upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any judgment, order
or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval,
authorization or order of, or qualification with, any governmental body, agency or court is required for the performance by the Company
of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in connection
with the offer and sale of the Shares.
(l) There
has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial
or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in
the Time of Sale Prospectus.
(m) There
are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company
to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include
such securities with the Shares registered pursuant to the Registration Statement.
(n) Each
preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed pursuant
to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable
rules and regulations of the Commission thereunder.
(o) Neither
the Company nor any Subsidiary is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default,
and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other similar agreement or instrument
to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or to which any of the property or
assets of the Company or any Subsidiary is subject; or (iii) in violation of any law or statute or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of each of clauses (ii) and (iii) above,
for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company’s
knowledge, no other party under any material contract or other agreement to which it or any Subsidiary is a party is in default in any
respect thereunder where such default would have a Material Adverse Effect.
5
(p) Since
the date of the most recent financial statements of the Company included or incorporated by reference in each of the Time of Sale Prospectus
and the Prospectus, there has not been (i) any Material Adverse Effect, or any development that could reasonably be expected to result
in a Material Adverse Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any
obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or the Subsidiaries,
which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock (other than
(A) the grant of additional options under the Company’s existing stock option plans, (B) changes in the number of outstanding
Common Stock of the Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible
into, Common Stock outstanding on the date hereof, (C) any repurchases of capital stock of the Company, (D) as described in
a proxy statement filed on Schedule 14A or a Registration Statement on Form S-4, or (E) otherwise publicly announced) or outstanding
long-term indebtedness of the Company or the Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made
on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise
disclosed in the Time of Sale Prospectus and the Prospectus.
(q) The
issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and, other than
as disclosed in the Time of Sale Prospectus and the Prospectus, are not subject to any preemptive rights, rights of first refusal or similar
rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Time of Sale Prospectus and the Prospectus
as of the dates referred to therein (other than (i) the grant of additional options under the Company’s existing stock option
plans, (ii) changes in the number of outstanding Common Stock of the Company due to the issuance of shares upon the exercise or conversion
of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, or (iii) any repurchases of capital
stock of the Company) and such authorized capital stock conforms to the description thereof set forth in the Time of Sale Prospectus and
the Prospectus. The description of the Common Stock in the Time of Sale Prospectus and the Prospectus is complete and accurate in all
material respects. Except as disclosed in or contemplated by the Time of Sale Prospectus and the Prospectus, the Company did not have
outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or
exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or other securities.
6
(r) Neither
the execution, delivery and performance by the Company of this Agreement, nor the issuance and sale of the Shares or the consummation
of the transactions contemplated by this Agreement or the Time of Sale Prospectus and the Prospectus, will conflict with, or will result
in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or has resulted in or will
result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms
of any contract or other agreement to which the Company may be bound or to which any of the property or assets of the Company is subject,
except (i) such conflicts, breaches or defaults as may have been waived and (ii) such conflicts, breaches and defaults that
would not have a Material Adverse Effect; nor will such action result (x) in any violation of the provisions of the organizational
or governing documents of the Company, or (y) in any material violation of the provisions of any statute or any order, rule or
regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or other government body
having jurisdiction over the Company, except where such violation would not have a Material Adverse Effect.
(s) No
consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or any governmental or regulatory
authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares,
and the consummation of the transactions contemplated by this Agreement or the Time of Sale Prospectus and the Prospectus, except for
such consents, approvals, authorizations, orders and registrations or qualifications (i) as may be required under applicable state
securities laws or by the by-laws and rules of the Financial Industry Regulatory Authority (“FINRA”) or the Exchange,
including any notices that may be required by the Exchange, in connection with the sale of the Shares by the Underwriters, (ii) as
may be required under the Securities Act and (iii) as have been previously obtained by the Company.
(t) Deloitte &
Touche LLP (“Deloitte”) and RSM US LLP (“RSM”, together with Deloitte, the “Accountants”),
whose respective reports on the consolidated financial statements of the Company are filed with the Commission as part of the Company’s
most recent Annual Report on Form 10-K filed with the Commission and incorporated into the Time of Sale Prospectus and the Prospectus,
were during the periods covered by their respective reports, independent public accountants within the meaning of the Securities Act and
the Public Company Accounting Oversight Board (United States). To the Company’s knowledge, the Accountants are not in violation
of the auditor independence requirements of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”),
with respect to the Company.
7
(u) All
agreements between the Company and third parties expressly referenced in the Time of Sale Prospectus and the Prospectus, other than such
agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company with the Commission,
are legal, valid and binding obligations of the Company and, to the Company’s knowledge, enforceable in accordance with their respective
terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors’ rights generally and by general equitable principles, (ii) enforceability may be limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) the indemnification
provisions of certain agreements may be limited by federal or state securities laws or public policy considerations in respect thereof,
and except for any unenforceability that, individually or in the aggregate, would not have a Material Adverse Effect.
(v) There
are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any Subsidiary
is a party or to which any of the properties of the Company or any Subsidiary is subject (i) other than proceedings accurately described
in all material respects in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and proceedings that would
not have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to
perform its obligations under this Agreement or to consummate the transactions contemplated by this Agreement or (ii) that are required
to be described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and are not so described.
(w) The
Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as currently conducted, as described in the Time of Sale Prospectus and the Prospectus (the “Permits”), except where
the failure to possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. Neither
the Company nor any Subsidiary has received written notice of any proceeding relating to revocation or modification of any such Permit
or has any reason to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such
revocation or renewal would not, individually or in the aggregate, have a Material Adverse Effect.
8
(x) Neither
the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term
leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect. The Company has not filed a report pursuant
to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form 10-K, indicating
that it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on any installment
on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate,
would have a Material Adverse Effect.
(y) Neither
the Company, nor any Subsidiary, nor, to the knowledge of the Company, any of their respective directors, officers or controlling persons
has taken, directly or indirectly, any action designed, or that has constituted or would cause or result in, under the Exchange Act or
otherwise, the stabilization or manipulation of the price of the Shares.
(z) Neither
the Company nor any Subsidiary or any related entities (i) is required to register as a “broker” or “dealer”
in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls
or is a “person associated with a member” or “associated person of a member” (within the meaning set forth in
the FINRA Manual).
(aa) The
Company and the Subsidiaries have good and valid title in fee simple to all items of real property and good and valid title to all personal
property described in the Time of Sale Prospectus and the Prospectus as being owned by them that are material to the businesses of the
Company or such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries or (ii) would not, individually
or in the aggregate, have a Material Adverse Effect. Any real property described in the Time of Sale Prospectus and the Prospectus as
being leased by the Company and the Subsidiaries is held by them under valid, existing and enforceable leases, except those that (A) do
not materially interfere with the use made or proposed to be made of such property by the Company or the Subsidiaries or (B) would
not, individually or in the aggregate, have a Material Adverse Effect.
9
(bb) The
Company and the Subsidiaries own or possess adequate enforceable rights to use all patents, patent applications, trademarks (both registered
and unregistered), trade names, trademark registrations, service marks, service mark registrations, Internet domain name registrations,
copyrights, copyright registrations, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary
or confidential information, systems or procedures) (collectively, the “Intellectual Property”), necessary for the
conduct of their respective businesses as conducted as of the date hereof, except to the extent that the failure to own or possess adequate
rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. The Company and the Subsidiaries have not received any written notice of any claim of infringement or conflict which asserted
Intellectual Property rights of others, which infringement or conflict, if the subject of an unfavorable decision, would result in a Material
Adverse Effect. There are no pending, or to the Company’s knowledge, threatened judicial proceedings or interference proceedings
challenging the Company’s or any Subsidiary’s rights in or to or the validity of the scope of any of the Company’s or
its Subsidiaries’ patents, patent applications or proprietary information. No other entity or individual has any right or claim
in any of the Company’s or any of its Subsidiary’s patents, patent applications or any patent to be issued therefrom by virtue
of any contract, license or other agreement entered into between such entity or individual and the Company or any Subsidiary or by any
non-contractual obligation, other than by written licenses granted by the Company or any Subsidiary. The Company has not received any
written notice of any claim challenging the rights of the Company or its Subsidiaries in or to any Intellectual Property owned, licensed
or optioned by the Company or any Subsidiary which claim, if the subject of an unfavorable decision, would result in a Material Adverse
Effect.
(cc) (i) The
Company and its subsidiaries use and have used any and all software and other materials distributed under a “free,” “open
source,” or similar licensing model (including but not limited to the MIT License, Apache License, GNU General Public License, GNU
Lesser General Public License and GNU Affero General Public License) (“Open Source Software”) in compliance with all
license terms applicable to such Open Source Software; and (ii) neither the Company nor any of its subsidiaries uses or distributes
or has used or distributed any Open Source Software in any manner that requires or has required (A) the Company or any of its subsidiaries
to permit reverse engineering of any software code or other technology owned by the Company or any of its subsidiaries or (B) any
software code or other technology owned by the Company or any of its subsidiaries to be (1) disclosed or distributed in source code
form, (2) licensed for the purpose of making derivative works or (3) redistributed at no charge.
(dd) The
Company and each of its Subsidiaries are in compliance with all applicable laws (including all Environmental Laws, as defined below) in
the jurisdictions in which it carries on business; the Company has not received a notice of non-compliance, nor knows of, nor has reasonable
grounds to know of, any facts that could give rise to a notice of non-compliance with any such laws, and is not aware of any pending change
or contemplated change to any applicable law or governmental position; in each case except which such failure to so be in compliance would
not result in a Material Adverse Effect.
10
(ee) The
Company and its Subsidiaries (i) are in compliance with any and all applicable federal, state, local and foreign laws relating to
the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively,
“Environmental Laws”); (ii) have received and are in compliance with all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses as described in the Time of Sale Prospectus
and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation
of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses
(i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals or
liability as would not, individually or in the aggregate, have a Material Adverse Effect. No facts or circumstances have come to the Company’s
attention with respect to its compliance with Environmental Laws or any permit, license or approval that could result in costs or liabilities
that could be expected, individually or in the aggregate, to have a Material Adverse Effect.
(ff) The
Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed
in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with
the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement is accurate. The Company
is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Company’s
filings with the Commission). Since the date of the latest audited financial statements of the Company filed with the Commission, there
has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely
to materially affect, the Company’s internal control over financial reporting (other than as set forth in the Company’s filings
with the Commission). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and
15d-15) that comply with the requirements of the Exchange Act. The Company’s certifying officers have evaluated the effectiveness
of the Company’s controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the fiscal
year most recently ended (such date, the “Evaluation Date”). The Company presented in its Form 10-K for the fiscal
year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the most recent Evaluation Date, and the “disclosure controls and procedures” are effective.
11
(gg) There
is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers,
in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules and
regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or each
former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has made all
certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and
other documents required to be filed by it or furnished by it to the Commission during the past twelve (12) months. For purposes of the
preceding sentence, “principal executive officer” and “principal financial officer” shall have the meanings given
to such terms in the Exchange Act Rules 13a-15 and 15d-15.
(hh) Neither
the Company nor any of its Subsidiaries is a party to any contract, agreement or understanding with any person (other than pursuant to
this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder’s
fee or like payment in connection with the offering and sale of the Shares.
(ii) No
labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge of the Company, is threatened
which would result in a Material Adverse Effect.
(jj) Neither
the Company nor any Subsidiary is or, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof
as described in the Time of Sale Prospectus and the Prospectus, will be required to register as an “investment company” or
an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as
amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).
(kk) There
are no transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any
of its affiliates and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose
entity (each, an “Off Balance Sheet Transaction”) that would affect materially the Company’s liquidity or the
availability of or requirements for its capital resources, including those Off Balance Sheet Transactions described in the Commission’s
Statement about Management’s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321;
FR-61), required to be described in the Time of Sale Prospectus or the Prospectus which have not been described as required.
12
(ll) The
Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be filed and paid
all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith,
except where the failure to do so would not have a Material Adverse Effect. Except as otherwise disclosed in or contemplated by the Time
of Sale Prospectus and the Prospectus, no tax deficiency has been determined adversely to the Company or any Subsidiary which has had,
or would have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other
governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material
Adverse Effect.
(mm) To
the knowledge of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”) that is maintained, administered or contributed to by
the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained in material
compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited
to ERISA and the Internal Revenue Code of 1986, as amended (the “Code”); (ii) no prohibited transaction, within
the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to
the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and (iii) for
each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated
funding deficiency” as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value
of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) equals or exceeds the present value of
all benefits accrued under such plan determined using reasonable actuarial assumptions, other than, in the case of (i), (ii) and
(iii) above, as would not have a Material Adverse Effect.
(nn) No
forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained
in the Time of Sale Prospectus and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than
in good faith.
(oo) Neither
the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described in the Time
of Sale Prospectus and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any
other regulation of such Board of Governors.
(pp) The
Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and the Subsidiaries
reasonably believe are adequate for the conduct of their business.
13
(qq) (i) Neither
the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary nor, to the Company’s
knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has, in the past five years, made any
unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation of applicable
law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office
or other person charged with similar public or quasi-public duty in violation of any applicable law or of the character required to be
disclosed in the Time of Sale Prospectus and the Prospectus; (ii) no relationship, direct or indirect, exists between or among the
Company or any Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of the Company
or any Subsidiary, on the other hand, that is required by the Securities Act to be described in the Time of Sale Prospectus and the Prospectus
that is not so described; (iii) no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any
affiliate of them, on the one hand, and the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand,
that is required by the rules of FINRA to be described in the Time of Sale Prospectus and the Prospectus that is not so described;
(iv) except as described in the Time of Sale Prospectus and the Prospectus, there are no material outstanding loans or advances or
material guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any of their respective officers or directors
or any of the members of the families of any of them; and (v) the Company has not offered, or caused any agent to offer, Common Stock
to any person with the intent to influence unlawfully (A) a customer or supplier of the Company or any Subsidiary to alter the customer’s
or supplier’s level or type of business with the Company or any Subsidiary or (B) a trade journalist or publication to write
or publish favorable information about the Company or any Subsidiary or any of their respective products or services.
(rr) Neither
the Company nor its Subsidiaries, nor any director, officer, or employee thereof, nor, to the Company’s knowledge, any agent or
representative of the Company or of any of its Subsidiaries or affiliates, has taken or will take any action in furtherance of an offer,
payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of
value, directly or indirectly, to any person to improperly influence official action by that person for the benefit of the Company or
its Subsidiaries or affiliates, or to otherwise secure any improper advantage, or to any person in violation of (a) the U.S. Foreign
Corrupt Practices Act of 1977, (b) the UK Bribery Act 2010, or (c) any other applicable law, regulation, order, decree or directive
having the force of law and relating to bribery or corruption (collectively, the “Anti-Corruption Laws”).
(ss) The
operations of the Company and each of its Subsidiaries are and have been conducted at all times in compliance with all applicable anti-money
laundering laws, rules, and regulations, including the financial recordkeeping and reporting requirements contained therein, and including
the Bank Secrecy Act of 1970, applicable provisions of the USA PATRIOT Act of 2001, the Money Laundering Control Act of 1986, and the
Anti-Money Laundering Act of 2020 (collectively, the “Anti-Money Laundering Laws”).
14
(tt) (i) Neither
the Company nor any of its Subsidiaries, nor any director, officer, employee, agent, affiliate, or representative of the Company or any
of its Subsidiaries, is an individual or entity (“Person”) that is, or is owned or controlled by one or more Persons
that are:
(A) the
subject of any sanctions administered or enforced by the United States Government (including the U.S. Department of the Treasury’s
Office of Foreign Assets Control and the U.S. Department of State), the United Nations Security Council, the European Union, His Majesty’s
Treasury, or any other relevant sanctions authority (collectively, “Sanctions”), or
(B) located,
organized or resident in a country or territory that is the subject of comprehensive territorial Sanctions (including, without limitation,
the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, or any other Covered Region of Ukraine identified
pursuant to Executive Order 14065, Crimea, Cuba, Iran, and North Korea).
(ii) The Company
and each of its Subsidiaries (a) have not, since the more recent of April 24, 2019 or 10 years prior to the date of the Agreement,
engaged in, (b) are not now engaged in, and (c) will not engage in, any dealings or transactions with any Person, or in any
country or territory, that at the time of the dealing or transaction is or was, or whose government is or was, the subject of Sanctions.
(uu) The
Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other Person:
(i) to fund or facilitate any activities or business of or with any Person or in any country or territory
that, at the time of such funding or facilitation, is, or whose government is, the subject of Sanctions;
(ii) to fund or facilitate any money laundering or terrorist financing activities; or
(iii) in any other manner that would cause or result in a violation of any Anti-Corruption Laws, Anti-Money
Laundering Laws, or Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor
or otherwise).
15
(vv) The
Company and its Subsidiaries have conducted and will conduct their businesses in compliance with the Anti-Corruption Laws, the Anti-Money
Laundering Laws, and Sanctions, and no investigation, inquiry, action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Anti-Corruption Laws, the Anti-Money
Laundering Laws, or Sanctions is pending or, to the knowledge of the Company, threatened. The Company and its Subsidiaries and affiliates
have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance
with the Anti-Corruption Laws, the Anti-Money Laundering Laws, Sanctions, and with the representations and warranties contained herein.
(ww) The
Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites,
applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material
respects as required in connection with the operation of the business of the Company as currently conducted, free and clear of all material
bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its Subsidiaries have implemented and
maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and
protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and
data, including all “Personal Data” (defined below) and all sensitive, confidential or regulated data (“Confidential
Data”) used in connection with their businesses. “Personal Data” means (i) a natural person’s
name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s
license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which
would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal
data” as defined by GDPR; (iv) any information which would qualify as “protected health information” under the
Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act (collectively, “HIPAA”); (v) any “personal information” as defined by the California Consumer
Privacy Act (“CCPA”); and (vi) any other piece of information that allows the identification of such natural person,
or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation.
There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied
without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating
to the same. The Company and its Subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems, Confidential Data, and Personal Data and to the protection of such IT
Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.
16
(xx) The
Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy
and security laws and regulations, including without limitation HIPAA, CCPA, and the European Union General Data Protection Regulation
(“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”). Neither the Company nor any Subsidiary:
(i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Privacy
Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law;
or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.
(yy) The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Time of Sale Prospectus and the
Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s
rules and guidelines applicable thereto.
(zz) No
Subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party
or is subject, from paying any dividends to the Company, from making any other distribution on such Subsidiary’s capital stock or
similar ownership interest, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring
any of such Subsidiary’s properties or assets to the Company or any other Subsidiary of the Company.
(aaa) No
relationship, direct or indirect, exists between or among the Company or any of its Subsidiaries, on the one hand, and the directors,
officers, stockholders, customers, suppliers or other affiliates of the Company or any of its Subsidiaries, on the other, that is required
by the Securities Act to be described in a registration statement to be filed with the Commission and that is not so described in the
each of the Time of Sale Prospectus and the Prospectus.
(bbb) None
of the Company or any of its affiliates or any other person acting on its or their behalf (other than the Underwriters, as to which no
representation is made) has solicited offers for, or offered or sold, the Shares by means of any form of general solicitation or general
advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning
of Section 4(a)(2) of the Securities Act, except as listed on Annex C.
(ccc) Nothing
has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included
or incorporated by reference in the Time of Sale Prospectus and the Prospectus is not based on or derived from sources that are reliable
and accurate in all material respects.
17
(ddd) There
are no debt securities or preferred stock of or guaranteed by the Company or any of its Subsidiaries that are rated by a “nationally
recognized statistical rating organization,” as such term is defined under Section 3(a)(62) under the Exchange Act.
(eee) No
material labor dispute with the employees of the Company or its Subsidiaries exists, or, to the knowledge of the Company, is imminent;
and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers,
manufacturers or contractors that could, singly or in the aggregate, have a Material Adverse Effect on the Company and its Subsidiaries,
taken as a whole.
(fff) The
Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including
any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee
benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.
(ggg) The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and
guidelines applicable thereto.
(hhh) The
Company (i) has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications
with the consent of Morgan Stanley with entities that are reasonably believed to be qualified institutional buyers within the meaning
of Rule 144A under the Securities Act or institutions that are reasonably believed to be accredited investors within the meaning
of Rule 501 under the Securities Act and (ii) has not authorized anyone other than Morgan Stanley to engage in Testing-the-Waters
Communications. The Company reconfirms that Morgan Stanley has been authorized to act on its behalf in undertaking Testing-the-Waters
Communications. The Company has not distributed any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the Securities Act. “Testing-the-Waters Communication” means any communication with potential
investors undertaken in reliance on Section 5(d) or Rule 163B of the Securities Act.
(iii) As
of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers,
none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered together with the Time of Sale Prospectus,
and (C) any individual Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.
18
2. Agreements
to Sell and Purchase. The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations
and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase
from the Company the respective numbers of Firm Shares set forth in Schedule I hereto opposite its name at $18.525 a share (the “Purchase
Price”).
On the basis of the representations and warranties
contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares,
and the Underwriters shall have the right to purchase, severally and not jointly, up to 7,110,000 Additional Shares at the Purchase Price,
provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to
any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares. Morgan Stanley may exercise
this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the
date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the
date on which such shares are to be purchased. Each purchase date must be at least one business day after the written notice is given
and may not be earlier than the closing date for the Firm Shares or later than ten business days after the date of such notice. On each
day, if any, that Additional Shares are to be purchased (an “Option Closing Date”), each Underwriter agrees, severally
and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as Morgan Stanley
may determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as
the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm
Shares.
3. Terms
of Public Offering. The Company is advised by Morgan Stanley that the Underwriters propose to make a public offering of their respective
portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in Morgan Stanley’s
judgment is advisable. The Company is further advised by Morgan Stanley that the Shares are to be offered to the public initially at $19.00
a share (the “Public Offering Price”) and to certain dealers selected by Morgan Stanley at a price that represents
a concession not in excess of $0.285 a share under the Public Offering Price.
4. Payment
and Delivery. Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York
City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on
April 16, 2026, or at such other time on the same or such other date, not later than ten business days after the Closing Date, as
shall be designated in writing by Morgan Stanley. The time and date of such payment are hereinafter referred to as the “Closing
Date.”
19
Payment for any Additional Shares shall be made
to the Company in Federal or other funds immediately available in New York City against delivery of such Additional Shares for the respective
accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in
Section 2 or at such other time on the same or on such other date, in any event not later than May 14, 2026, as shall be designated
in writing by Morgan Stanley.
The Firm Shares and Additional Shares shall be
registered in such names and in such denominations as Morgan Stanley shall request not later than one full business day prior to the Closing
Date or the applicable Option Closing Date, as the case may be. The Firm Shares and Additional Shares shall be delivered to Morgan Stanley
on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer
taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor.
5. Conditions
to the Underwriters’ Obligations. The obligations of the Company to sell the Shares to the Underwriters and the several obligations
of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the Registration Statement
shall have become effective not later than 4:30 p.m. (New York City time) on the date hereof.
The several obligations of the Underwriters are
subject to the following further conditions:
(a) Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date:
(i) no
order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to
Section 8A under the Securities Act shall be pending before or threatened by the Commission;
(ii) there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the
Company or any of the Subsidiaries by any “nationally recognized statistical rating organization,” as such term is defined
in Section 3(a)(62) of the Exchange Act; and
(iii) there
shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in
the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus
that, in Morgan Stanley’s judgment, is material and adverse and that makes it, in Morgan Stanley’s judgment, impracticable
to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.
20
(b) The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company,
to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties
of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the
agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.
The officer signing and delivering such certificate
may rely upon the best of his or her knowledge as to proceedings threatened.
(c) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Paul, Weiss, Rifkind, Wharton &
Garrison LLP, outside counsel for the Company, dated the Closing Date, in form and substance satisfactory to Morgan Stanley.
(d) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of DLA Piper LLP (US), counsel for the Underwriters,
dated the Closing Date, in form and substance satisfactory to Morgan Stanley.
(e) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Underwriters, from the Accountants, containing statements and information
of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements
and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; provided
that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof.
(f) The
chief financial officer of the Company shall have furnished to you on each of the date hereof and the Closing Date, a certificate as to
the accuracy of certain financial information, dated as of each such date, respectively, in form and substance reasonably satisfactory
to you.
(g) The
“lock-up” agreements, each substantially in the form of Exhibit A hereto, between Morgan Stanley and certain shareholders,
officers and directors of the Company relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain
other securities, delivered to Morgan Stanley on or before the date hereof (the “Lock-up Agreements”), shall be in
full force and effect on the Closing Date.
(h) The
several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to Morgan Stanley on the applicable
Option Closing Date of the following:
(i) a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date;
21
(ii) an
opinion and negative assurance letter of Paul, Weiss, Rifkind, Wharton & Garrison LLP, outside counsel for the Company, dated
the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect
as the opinion required by Section 5(c) hereof;
(iii) an
opinion and negative assurance letter of DLA Piper LLP (US), counsel for the Underwriters, dated the Option Closing Date, relating to
the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 5(d) hereof;
(iv) a
letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from the Accountants, substantially in the
same form and substance as the letter furnished to the Underwriters pursuant to Section 5(e) hereof; provided that the
letter delivered on the Option Closing Date shall use a “cut-off date” not earlier than two business days prior to such Option
Closing Date;
(v) the
chief financial officer of the Company shall have furnished to you on the Option Closing Date, a certificate as to the accuracy of certain
financial information, dated as of the Option Closing Date, in form and substance reasonably satisfactory to you; and
(vi) such
other documents as Morgan Stanley may reasonably request with respect to the good standing of the Company, the due authorization and issuance
of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares.
6. Covenants
of the Company. The Company covenants with each Underwriter as follows:
(a) To
furnish to Morgan Stanley, without charge, a signed copy of the Registration Statement (including exhibits thereto and documents incorporated
by reference) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto but
including documents incorporated by reference) and to furnish to Morgan Stanley in New York City, without charge, prior to 10:00 a.m. New
York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 6(e) or
6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference therein, and any
supplements and amendments thereto or to the Registration Statement as Morgan Stanley may reasonably request.
22
(b) Before
amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to Morgan Stanley a copy
of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which Morgan Stanley reasonably
objects, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.
(c) To
furnish to Morgan Stanley a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred to by
the Company and not to use or refer to any proposed free writing prospectus to which Morgan Stanley reasonably objects.
(d) Not
to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under
the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have
been required to file thereunder.
(e) If
the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective
purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus
in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or condition exist
as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file,
or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with
applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer
upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as
so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective
purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration
Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.
(f) If,
during such period after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus
(or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection
with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare,
file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses Morgan Stanley
will furnish to the Company) to which Shares may have been sold by Morgan Stanley on behalf of the Underwriters and to any other dealers
upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented
will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of
the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with
applicable law.
23
(g) To
endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as Morgan Stanley shall
reasonably request.
(h) To
make generally available to the Company’s security holders and to Morgan Stanley as soon as practicable an earnings statement covering
a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which
shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.
(i) Whether
or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all
expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses
of the Company’s counsel and the Company’s accountants in connection with the registration and delivery of the Shares under
the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred
to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing
and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) all costs and expenses
related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii) the
cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state
securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as
provided in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters
in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all filing fees and
the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering
of the Shares by FINRA, (v) all fees and expenses in connection with the preparation and filing of the registration statement on
Form 8-A relating to the Common Stock and all costs and expenses incident to listing the Shares on the Exchange, (vi) the cost
of printing certificates representing the Shares, (vii) the costs and charges of any transfer agent, registrar or depositary, (viii) the
costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the
marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any
electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged
in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives
and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show, (ix) the
document production charges and expenses associated with printing this Agreement and (x) all other costs and expenses incident to
the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood,
however, that except as provided in this Section, Section 8 entitled “Indemnity and Contribution” and the last paragraph
of Section 11 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel,
stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make.
24
(j) If
at any time following the distribution of any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405
under the Securities Act there occurred or occurs an event or development as a result of which such Testing-the-Waters Communication included
or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify
Morgan Stanley and will promptly amend or supplement, at its own expense, such Testing-the-Waters Communication to eliminate or correct
such untrue statement or omission.
(k) The
Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed
Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company
undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification
of the foregoing Certification.
The Company also covenants with each Underwriter
that, without the prior written consent of Morgan Stanley on behalf of the Underwriters, it will not, and will not publicly disclose an
intention to, during the period ending 30 days after the date of the Prospectus (the “Restricted Period”), (1) offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise
or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock.
25
The restrictions contained in the preceding paragraph
shall not apply to (A) the Shares to be sold hereunder, (B) the issuance by the Company of shares of Common Stock upon the exercise
of an option or warrant or the conversion of a security outstanding on the date hereof as described in each of the Time of Sale Prospectus
and Prospectus, or (C) facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided that (i) such plan
does not provide for the transfer of Common Stock during the Restricted Period and (ii) to the extent a public announcement or filing
under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement
or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period.
7. Covenants
of the Underwriters. Each Underwriter, severally and not jointly, covenants with the Company not to take any action that would result
in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf
of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.
8. Indemnity
and Contribution. (a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any
Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate
of any Underwriter within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and
liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating
any such action or claim) that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement
thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that
the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any road show as defined in
Rule 433(h) under the Securities Act (a “road show”), the Prospectus or any amendment or supplement thereto, or
any Testing-the-Waters Communication, or arise out of, or are based upon, any omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims,
damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or omission
made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter
through Morgan Stanley expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters
through Morgan Stanley consists of the information described as such in paragraph (b) below.
26
(b) Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information
relating to such Underwriter furnished to the Company in writing by such Underwriter through Morgan Stanley expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or
any amendment or supplement thereto, it being understood and agreed upon that the only such information furnished by any Underwriter consists
of the following information under the caption “Underwriting” in the Prospectus furnished on behalf of each Underwriter: the
concession figure appearing in the third paragraph and the information contained in the thirteenth paragraph describing passive market
making and stabilization.
27
(c) In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify
the person against whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying party,
upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified
party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel
related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees
and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified
party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party shall
not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties
and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Morgan Stanley,
in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b).
The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from
and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated
by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding
effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying
party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with
such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party,
effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party
and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of
such indemnified party from all liability on claims that are the subject matter of such proceeding.
(d) To
the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient
in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu
of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result
of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the allocation provided
by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters
on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well
as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on
the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds
from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering
Price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Underwriters’ respective obligations
to contribute pursuant to this Section 8 are several in proportion to the respective number of Shares they have purchased hereunder,
and not joint.
28
(e) The
Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies
provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any
indemnified party at law or in equity.
(f) The
indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of the
Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this
Agreement, (ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate
of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance
of and payment for any of the Shares.
9. [Reserved.]
10. Termination.
The Underwriters may terminate this Agreement by notice given by Morgan Stanley to the Company, if after the execution and delivery of
this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i) trading generally shall have
been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the NASDAQ
Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading
of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption
in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any moratorium on commercial
banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak
or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in Morgan Stanley’s judgment, is
material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in Morgan Stanley’s
judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated
in the Time of Sale Prospectus or the Prospectus.
29
11. Effectiveness;
Defaulting Underwriters. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
If, on the Closing Date or an Option Closing Date,
as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase
hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused
to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall
be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedule I
bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions
as Morgan Stanley may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase on such date; provided that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant
to this Agreement be increased pursuant to this Section 11 by an amount in excess of one-ninth of such number of Shares without the
written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares
and the aggregate number of Firm Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Firm
Shares to be purchased on such date, and arrangements satisfactory to Morgan Stanley and the Company for the purchase of such Firm Shares
are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter
or the Company. In any such case either Morgan Stanley or the Company shall have the right to postpone the Closing Date, but in no event
for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus,
in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs
is more than one-tenth of the aggregate number of Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters
shall have the option to (i) terminate their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing
Date or (ii) purchase not less than the number of Additional Shares that such non-defaulting Underwriters would have been obligated
to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability
in respect of any default of such Underwriter under this Agreement.
If this Agreement shall be terminated by the Underwriters,
or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions
of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will
reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket
expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement
or the offering contemplated hereunder.
30
12. Entire
Agreement. (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the
extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company
and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct
of the offering, and the purchase and sale of the Shares.
(b) The
Company acknowledges that in connection with the offering of the Shares: (i) the Underwriters have acted at arm’s length, are
not agents of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those
duties and obligations set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent
not superseded by this Agreement), if any, (iii) the Underwriters may have interests that differ from those of the Company, and (iv) none
of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment
advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company waives to the full
extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in
connection with the offering of the Shares.
13. Recognition
of the U.S. Special Resolution Regimes. (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
(b) In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.
For purposes
of this Section a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall
be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a
“covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered
bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI”
as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). “Default Right” has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
31
14. Counterparts.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument.
15. Applicable
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.
16. Headings.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of
this Agreement.
17. Notices.
All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to Morgan Stanley at 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal
Department; and if to the Company shall be delivered, mailed or sent to 9 Federal Street, Easton, Maryland 21601, Attention: Stefanie
Fleischmann, Chief Legal Officer.
Very truly yours,
TeraWulf Inc.
By:
/s/ Patrick Fleury
Name: Patrick Fleury
Title: Chief Financial Officer
32
Accepted as of the date hereof
Morgan Stanley & Co. LLC
Acting severally on behalf of themselves and the several Underwriters named in Schedule I hereto.
By:
Morgan Stanley & Co. LLC
By:
/s/ Daniel Croitoru
Name:Daniel Croitoru
Title: Vice President
SCHEDULE I
Underwriter
Number of Firm Shares To
Be Purchased
Morgan Stanley & Co. LLC
11,850,000
BofA Securities, Inc.
5,925,000
Citigroup Global Markets Inc.
5,925,000
TD Securities (USA) LLC
5,925,000
Wells Fargo Securities, LLC
5,925,000
Citizens JMP Securities, LLC
5,925,000
Santander US Capital Markets
5,925,000
Total:
47,400,000
I-1
SCHEDULE II
Time of Sale Prospectus
1. Preliminary Prospectus dated April 14, 2026 as filed with the Commission on April 14, 2026
2. Orally communicated pricing information:
· Public Offering Price: $19.00
· Number of Firm Shares: 47,400,000
· Maximum Number of Additional Shares: 7,110,000
· Closing Date: April 16, 2026
II-1
EXHIBIT A
[FORM OF LOCK-UP AGREEMENT]
_____________, 20__
Morgan Stanley & Co. LLC
c/o Morgan Stanley & Co. LLC
1585 Broadway
New York, NY 10036
Ladies and Gentlemen:
The undersigned understands that Morgan Stanley &
Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”)
with TeraWulf Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public
Offering”) by the several Underwriters, including Morgan Stanley (the “Underwriters”), of 47,400,000 shares
(the “Shares”) of common stock, $0.001 per share par value, of the Company (the “Common Stock”).
To induce the Underwriters that may participate
in the Public Offering to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of Morgan Stanley on behalf of the Underwriters, it will not, and will not cause any direct or indirect affiliate
to, during the period commencing on the date hereof and ending 30 days after the date of the final prospectus (the “30th Day”)
or, if the 30th Day is not a Trading Day, immediately after the close of the last Trading Day immediately preceding the 30th Day (the
“Restricted Period”) relating to the Public Offering (the “Prospectus”), (1) offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be
deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission
and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, “Lock-Up
Securities”), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any
of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect
to the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing. The undersigned
acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements
(including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof,
forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably
be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic
consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement
(or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise. For purposes of this
Lock-Up Agreement, a “Trading Day” is a day on which The Nasdaq Capital Market is open for the buying and selling of
securities.
1
Notwithstanding the foregoing, the undersigned may:
(a) transfer the undersigned’s Lock-Up Securities:
(i) as a bona fide gift or gifts, or for bona
fide estate planning purposes,
(ii) by will or intestacy,
(iii) to any trust for the direct or indirect
benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of
the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, “immediate family” shall
mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),
(iv) to a partnership, limited liability company
or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the
outstanding equity securities or similar interests,
(v) to a nominee or custodian of a person
or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,
(vi) if the undersigned is a corporation,
partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability
company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933,
as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under
common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is
a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as
part of a distribution to members or shareholders of the undersigned,
(vii) by operation of law, such as pursuant
to a qualified domestic order, divorce settlement, divorce decree or separation agreement,
(viii) to the Company from an employee of
the Company upon death, disability or termination of employment, in each case, of such employee,
2
(ix) as part of a sale of the undersigned’s
Lock-Up Securities acquired in open market transactions after the closing date for the Public Offering,
(x) to the Company in connection with the
vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including,
in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and tax and
remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights,
provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this
Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant
to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is
described in, or which description is incorporated by reference into, the Time of Sale Prospectus and the Prospectus, [or]
[(xi) sales in open market transactions during
the Restricted Period to generate such amount of net proceeds to the undersigned from such sales (after deducting commissions) in an aggregate
amount up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of the vesting and/or settlement
of Company equity awards held by the undersigned and issued pursuant a stock incentive plan or other equity award plan which is described
in, or which description is incorporated by reference into, the Time of Sale Prospectus and the Prospectus that vest and/or settle during
the Restricted Period, and provided, for the avoidance of doubt, any shares of Common Stock or other Lock-Up Securities retained by the
undersigned after giving effect to this provision, shall be subject to the terms of this letter agreement, or]
[(xii)] pursuant to a bona fide third-party tender
offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders
of the Company’s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, “Change
of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction
or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such
person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving
entity));
provided
that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned’s
Lock-Up Securities shall remain subject to the provisions of this Letter Agreement; and
further provided
that (A) in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such
transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the
Representative a lock-up letter in the form of this Letter Agreement, (B) in the case of any transfer or distribution pursuant to
clause (a) (i), (iii), (iv), (v), (vi), and (ix), no filing by any party (donor, donee, devisee, transferor, transferee, distributer
or distributee) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other public announcement
shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5
made after the expiration of the Restricted Period referred to above) and (C) in the case of any transfer or distribution pursuant
to clause (a)(ii), (vii), (viii), [and] (x) [and (xi)] it shall be a condition to such transfer that no public filing, report or
announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report
or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution
shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto
the nature and conditions of such transfer;
3
(b) exercise outstanding options, settle restricted
stock units or other equity awards or exercise warrants pursuant to plans described in, or which description is incorporated by reference
into, the Time of Sale Prospectus and the Prospectus; provided that any Lock-up Securities received upon such exercise, vesting or settlement
shall be subject to the terms of this Letter Agreement;
(c) convert outstanding preferred stock, warrants
to acquire preferred stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided
that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement;
(d) sell or transfer of shares of Common Stock
pursuant to a written plan for trading securities that is designed to satisfy the requirements of Rule 10b5-1 under the Exchange
Act (a “10b5-1 Plan”) in effect as of the date of the Prospectus and disclosed to the Representative prior to the date
hereof, provided that any filing under Section 16 of the Exchange Act made in connection with such sales shall clearly indicate in
the footnotes thereto that such disposition of shares of Common Stock was pursuant to a 10b5-1 Plan; [and]
[(e)] transfer up to a maximum of 3,000,000 shares
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pledged in a bona fide transaction to
third parties as collateral to secure obligations pursuant to lending or other arrangements between such third parties (or their affiliates
or designees) and the undersigned and/or its affiliates or any similar arrangement relating to a financing arrangement for the benefit
of the undersigned and/or its affiliates, provided that in the case of pledges or similar arrangements under this clause (e), any such
pledgee or other party shall, upon foreclosure on the pledged securities, sign and deliver a lock-up agreement substantially in the form
of this agreement, and provided further that no filing under the Exchange Act, or any other public filing or disclosure, of such transfer
by or on behalf of the undersigned, shall be voluntarily made during the Restricted Period; and]
[(e)][(f)] establish trading plans pursuant to
Rule 10b5-1 under the Exchange Act for the transfer of shares of Lock-Up Securities; provided that (1) such plans do
not provide for the transfer of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange
Act or other public announcement shall be required or made voluntarily in connection with such trading plan.
4
In furtherance of the foregoing, the Company, and
any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline
to make any transfer of securities if such transfer would constitute a violation or breach of this agreement.
The undersigned understands that the Company and
the Underwriters are relying upon this agreement in proceeding toward consummation of the Public Offering. The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this agreement. All authority herein conferred or agreed
to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives
of the undersigned. This agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
The undersigned acknowledges and agrees that the
Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned
with respect to the Public Offering of the Shares and the undersigned has consulted their own legal, accounting, financial, regulatory
and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may
provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Public
Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any Shares at the
price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter
is making such a recommendation.
Whether or not the Public Offering actually occurs
depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
The undersigned understands that, if the Underwriting
Agreement does not become effective by April 31, 2026, or if the Underwriting Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder, or if either
the Company, on the one hand, or the Representative, on the other hand, notifies the other in writing that it does not intend to proceed
with the Public Offering, the undersigned shall be released from all obligations under this agreement.
5
This agreement and any claim, controversy or dispute
arising under or related to this agreement shall be governed by and construed in accordance with the laws of the State of New York.
Very truly yours,
(Name)
(Address)
6
EX-5.1 — EXHIBIT 5.1
EX-5.1
Filename: tm2611661d9_ex5-1.htm · Sequence: 3
Exhibit 5.1
Paul,
Weiss, Rifkind, Wharton & Garrison LLP
Brussels
Hong Kong
1285 Avenue of the Americas
London
New York, NY 10019-6064
Los Angeles
+1 212 373 3000
San Francisco
Tokyo
Toronto
Washington,
D.C.
Wilmington
April 16, 2026
TeraWulf Inc.
9 Federal Street,
Easton, Maryland 21601
Ladies and Gentlemen:
We have acted as special counsel
to TeraWulf Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3ASR (File
No. 333-295042) (the “Registration Statement”) of the Company, filed with the Securities and Exchange Commission (the “Commission”)
pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder (the “Rules”).
You have asked us to furnish our opinion as to the legality of up to 54,510,000 shares of the Company’s common stock, par value
$0.001 per share (the “Common Stock”) (including shares issuable by the Company upon exercise of the underwriter’s option
to purchase additional shares of Common Stock), which are registered under the Registration Statement and which are being sold pursuant
to an Underwriting Agreement dated April 14, 2026 (the “Underwriting Agreement”), by and among Morgan Stanley & Co. LLC,
as representative of the several underwriters named on Schedule I thereto (the “Underwriters”), and the Company.
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 2
TeraWulf Inc.
In connection with the furnishing
of this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction, of the following documents
(collectively, the “Documents”):
1. the Registration Statement;
2. the preliminary prospectus supplement dated April 14, 2026 (the “Preliminary Prospectus”);
3. the final prospectus supplement dated April 14, 2026 (the “Final Prospectus”); and
4. the Underwriting Agreement.
In addition, we have examined (i)
such corporate records of the Company that we have considered appropriate, including a copy of the Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws of the Company, certified by the Company as in effect on the date of this letter, and copies
of resolutions of the board of directors of the Company (the “Board”) and the pricing committee of the Board relating to the
issuance of the Common Stock, certified by the Company, and (ii) such other certificates, agreements and documents that we deemed relevant
and necessary as a basis for the opinion expressed below. We have also relied upon the factual matters contained in the representations
and warranties of the Company made in the Documents and upon certificates of public officials and the officers of the Company.
In our examination of the documents
referred to above, we have assumed, without independent investigation, the genuineness of all signatures, the legal capacity of all individuals
who have executed any of the documents reviewed by us, the authenticity of all documents submitted to us as originals, the conformity
to the originals of all documents submitted to us as certified, photostatic, reproduced or conformed copies of valid existing agreements
or other documents, the authenticity of all the latter documents and that the statements regarding matters of fact in the certificates,
records, agreements, instruments and documents that we have examined are accurate and complete.
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 3
TeraWulf Inc.
Based upon the above, and subject
to the stated assumptions, exceptions and qualifications, we are of the opinion that the Common Stock has been duly authorized by all
necessary corporate action on the part of the Company and, when issued, delivered and paid for as contemplated in the Registration Statement
and in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and non-assessable.
The opinion expressed above is limited
to the General Corporation Law of the State of Delaware. Our opinion is rendered only with respect to the laws, and the rules, regulations
and orders under those laws, that are currently in effect.
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP 4
TeraWulf Inc.
We hereby consent to use of this
opinion as an exhibit to the Company’s Current Report on Form 8-K filed by the Company with the Commission filed on or about the
date hereof for incorporation by reference into the Registration Statement and to the use of our name under the heading “Legal Matters”
contained in the Registration Statement, the Preliminary Prospectus and the Final Prospectus. In giving this consent, we do not thereby
admit that we come within the category of persons whose consent is required by the Act or the Rules.
Very truly yours,
/s/ Paul, Weiss, Rifkind,
Wharton & Garrison LLP
PAUL, WEISS, RIFKIND, WHARTON
& GARRISON LLP
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: tm2611661d9_ex99-1.htm · Sequence: 4
Exhibit 99.1
TeraWulf Announces Closing of Common Stock Offering
EASTON, Maryland. — April 16,
2026 — TeraWulf Inc. (NASDAQ: WULF) (the “Company” or “TeraWulf”) today announced the closing of
its previously announced public offering of 54,510,000 shares of its common stock (the “Offering”) at a price of $19.00 per
share, including the full exercise by the underwriters of their option to purchase up to an additional 7,110,000 shares of common stock.
TeraWulf intends to use the net proceeds from the Offering to fund
a portion of the construction costs for its planned data center campus in Hawesville, Kentucky, including repayment in full of amounts
outstanding under its bridge credit facility, as well as for future site acquisitions and general corporate purposes.
Morgan Stanley is acting as lead bookrunning manager for the Offering.
BofA Securities, Citigroup, TD Cowen and Wells Fargo Securities are acting as joint bookrunners. Citizens Capital Markets and Santander
are acting as co-managers. Cantor Fitzgerald is serving as the Company’s equity capital markets advisor.
The Offering was made by means of a prospectus
supplement under TeraWulf’s effective shelf registration statement on Form S-3ASR, as filed with the Securities and
Exchange Commission (the “SEC”).
This press release does not constitute an offer to sell or a solicitation
of an offer to buy any securities, nor does it constitute an offer, solicitation or sale of any securities in any jurisdiction in which
such offer, solicitation or sale is unlawful. The Offering was made only by means of a prospectus supplement relating to such Offering
and the accompanying prospectus. Copies of the final prospectus supplement for the Offering and the accompanying prospectus can be obtained
from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, email: prospectus@morganstanley.com,
telephone: (866) 718-1649.
About TeraWulf
TeraWulf develops, owns, and operates environmentally sustainable,
industrial-scale data center infrastructure in the United States, purpose-built for high-performance computing (HPC) hosting and bitcoin
mining. Led by a team of veteran energy infrastructure entrepreneurs, TeraWulf is committed to delivering scalable, low-carbon compute
capacity for next-generation AI and HPC customers.
Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements other than statements of historical fact, including statements about beliefs, expectations, targets
or goals and the use of proceeds of the Offering, are, or may be deemed to be, forward-looking statements. Forward-looking statements
are typically identified by words such as “expects,” “intends,” “will,” “anticipates,”
“believes,” “confident,” “continue,” “propose,” “seeks,” “could,”
“may,” “should,” “estimates,” “forecasts,” “might,” “goals,” “objectives,”
“targets,” “planned,” “projects,” and, in each case, their negative or other various or comparable
terminology and similar expressions. Without limiting the generality of the preceding sentence, any time we use forward-looking statements,
we intend to clearly express that the information deals with possible future events and is forward-looking in nature. However, the absence
of these words or similar expressions does not mean that a statement is not-forward-looking.
These forward-looking statements are
based on the current expectations and beliefs of TeraWulf’s management and are subject to known and unknown risks, uncertainties
and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. For TeraWulf, particular
uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include,
without limitation:
· the ability to complete our data center campuses and future strategic growth
initiatives in a timely manner or within anticipated cost estimates;
· the ability to attract additional customers to lease our HPC data centers;
· TeraWulf's ability to perform under its existing data center lease agreements;
· the need to raise additional capital to meet our business requirements in
the future, which may be costly or difficult to obtain or may not be obtained (in whole or in part) and, if obtained, could significantly
dilute the ownership interests of TeraWulf’s shareholders;
· the availability and cost of power as well as electrical infrastructure equipment
necessary to maintain and grow the business and operations of TeraWulf;
· adverse geopolitical or economic conditions, including a high inflationary
environment and the implementation of new tariffs and more restrictive trade regulations;
· security threats or unauthorized or impermissible access to our data centers,
our operations or our digital wallet;
· counterparty risk with respect to our digital asset custodian and our mining
pool provider;
· employment workforce factors, including the loss of key employees;
· changes in governmental safety, health, environmental and other regulations,
which could require significant expenditures;
· conditions in the cryptocurrency mining industry, including any prolonged
substantial reduction in the value of bitcoin;
· currency exchange rate fluctuations; and
· other risks, uncertainties and factors, including those set forth in the
Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year
ended December 31, 2025.
These forward-looking statements reflect
our views with respect to future events as of the date of this press release and are based on assumptions and subject to risks and uncertainties.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent
our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to
update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the
date of this press lease. We anticipate that subsequent events and developments will cause our views to change. You should read this press
release completely and with the understanding that our actual future results may be materially different from what we expect. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may
undertake. We qualify all of our forward-looking statements by these cautionary statements. Investors are referred to the full discussion
of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in TeraWulf’s
filings with the SEC, which are available at www.sec.gov.
Investors:
Investors@terawulf.com
Media:
Media@terawulf.com
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Cover
Apr. 14, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Apr. 14, 2026
Entity File Number
001-41163
Entity Registrant Name
TERAWULF INC.
Entity Central Index Key
0001083301
Entity Tax Identification Number
87-1909475
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
9 Federal Street
Entity Address, City or Town
Easton
Entity Address, State or Province
MD
Entity Address, Postal Zip Code
21601
City Area Code
410
Local Phone Number
770-9500
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common stock, par value $0.001 per share
Trading Symbol
WULF
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration